CP 42,096 is an analgesic drug which acts as a cannabinoid agonist. It was developed by Pfizer in the 1980s as part of the research that led to the development of levonantradol, and is more potent than THC but less potent than newer compounds such as CP 55,244.
See also A-41988 CP 47,497 CP 55,940 Canbisol Hexahydrocannabinol
References